Treating insulin resistance: Future prospects

Diabetes and Vascular Disease Research

Volumn 4, Issue 1, 2007, Pages 20-31

  Bailey, Clifford J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Insulin mimetics; Insulin potentiators; Insulin resistance; Phosphatase inhibitors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; BROMOCRIPTINE; C PEPTIDE; GROWTH HORMONE; INOSITOL DERIVATIVE; INSULIN RECEPTOR; ISOFERULIC ACID; LEPTIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIOGLITAZONE; PROTEIN KINASE C; PROTEIN SERINE KINASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; RESISTIN; RESVERATROL; RIMONABANT; ROSIGLITAZONE; RUBOXISTAURIN; SALICYLIC ACID; SIBUTRAMINE; SOMATOMEDIN C; THIOCTIC ACID; UNINDEXED DRUG; VISFATIN;

ADIPOCYTE; BETA CHAIN; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; NEGATIVE FEEDBACK; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENYLATE KINASE; ADIPOCYTES; ANTI-OBESITY AGENTS; CYTOKINES; GLUCOCORTICOIDS; GLUCOSE; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; LIPID METABOLISM; MINERALS; PPAR GAMMA; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; VITAMINS;

EID: 34247547470     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2007.002     Document Type: Review

References (170)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
2. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts and different goals. Endocrinol Metab Clin N Am 2004;33:283-303.
3. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
4. Grundy SM, Hansen B, Smith SC, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association, National Heart, Lung and Blood Institute, American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551-6.
5. Isaacsohn JL, Troendle AJ, Orloff DG. Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia and the metabolic syndrome. Am J Cardiol 2004;93(suppl 11A):49C-52C.
6. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Revs 1997; 5:117-269.
7. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-6.
8. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
9. Pirola L, Johnston AM, Van Obberghen E. Modulation of insulin action. Diabetologia 2004;47:170-84.
10. Bailey CJ. Insulin resistance and antidiabetic drugs. Biochem Pharmacol 1999;58:1511-20.
11. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999;58(suppl 1):31-9.
12. Kumar N, Dey CS. Metformin enhances insulin signaling in insulin-dependent and -independent pathways in insulin resistant muscle cells. Br J Pharmacol 2002;137:329-36.
13. Gunton JE,Delhanty PJ, Takahashi SI, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin receptor substrate-2. J Clin Endocr Metab 2003;88:1323-32.
14. Wiernsperger NF. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diab Metab 1999;25:110-27.
15. Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074-81.
16. Einhorn D, Aroda VR, Henry RR. Glitazones and the management of insulin resistance: what do they do and how might they be used. Endocrinol Metab Clin N Am 2004;33:595-616.
17. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
18. Hevener AL, Reichart D, Janez A, Olefsky J. Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male Wistar rats. Diabetes 2001;50:2316-22.
19. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003;14:137-45.
20. Zhang B, Salituro G, Szalkowski D et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999; 284:974-7.
21. Li M, Youngren JF, Manchem VP et al. Small molecule insulin receptor activators potentiate insulin action in insulin resistant cells. Diabetes 2001;50:2323-8.
22. Manchem VP, Goldfine ID, Kohanski RA et al. A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo. Diabetes 2001;50:824-30.
23. Wahren J, Ekberg K, Johansson J. Role of C-peptide in human physiology. Am J Physiol 2000;278:E759-E768.
24. Zierath JR, Handberg A, Tally M, Wallberg-Henriksson H. C-peptide stimulates glucose transport in human skeletal muscle independent of insulin receptor and tyrosine kinase activation. Diabetologia 1996;39:306-13.
25. Grunberger G, Quiang X, Li Z et al. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 2001;44:1247- 57.
26. Calera M, Vallega G, Pilch P. Dynamics of protein tyrosine phosphatases in rat adipocytes. J Biol Chem 1997;100:449-58.
27. Elchebly M, Payette P, Michaliszyn E. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999;283:1544-8.
28. Gum RJ, Gaede LL, Koterski SL et al. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 2003;52:21-8.
29. Ahmad F, Azevedo JJ, Cortright R, Dohm G, Goldstein B. Alterations in skeletal muscle protein tyrosine phosphatase activity and expression in insulin resistant human obesity and diabetes. J Clin Invest 1997;100:449- 58.
30. Wrobel J, Sredy J, Moxham C et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtha[2,3-d]furans and 11-arylbenzo[b]naphtha[2,3-d-] thiophenes. J Med Chem 1999;42:3199-202.
31. Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003;12:223-33.
32. Xic L, Lee SY, Andersen JN et al. Cellular effects of small molecule PTP1B inhibitors on insulin signaling. Biochemistry 2003;42:12792-804.
33. Lund IK, Andersen HS, Iversen LF, Olsen OH, Moller KB. Structure-based design of selective and potent inhibitors of protein tyrosine phosphatase B. J Biol Chem 2004;279:24226-35.
34. Balkan B, Beeler S, Fan C, Orlowski L, Whitehouse D, Dean DJ. Pharmacological inhibition of PTP1B prevents development of diet-induced obesity and insulin resistance. Diabetes 2005;54(suppl 1): 618-P.
35. Morrison CD, White CL, Wang Z et al. increased hypothalamic PTP1B contributes to leptin resistance with age. Endocrinol 2007; 148:435-40.
36. Tsiani E, Fantus IG. Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol Metab 1997;8:51-8.
37. Vercauteren M, Remy E, Devaux C et al. Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure. Circulation 2006;114:2498.
38. Le Roith D. Insulin-like growth factors. N Engl J Med 1997;336:633-40.
39. Nyomba BLG, Berard L, Murphy IJ. Free insulin-like growth factor 1 (IGF-1) in healthy subjects: relationship with IGF-1 binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997;82:2177-81.
40. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor 1 and insulin-like growth factor binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000;85:1518-24.
41. O'Connell T, Clemmons DR. IGF-1/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab 2003;87:4356-60.
42. Ng FM. Human growth hormone fragments. In: Bailey CJ, Flatt PR (eds). New antidiabetic drugs. London: Smith-Gordon, 1990; pp 197-206.
43. Ueno N, Inui A, Asakawa A et al. Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with type II diabetes mellitus. Diabetologia 2002;45:792-7.
44. White MF. IRS proteins and the common path to diabetes. Am J Physiol 2002;283:E413-E422.
45. Pederson TM, Kramer DL, Rondinone CM. Serine threonine phosphorylation of IRS-1 triggers its degradation; possible regulation by tyrosine phosphorylation. Diabetes 2001;50:24-31.
46. Itani S, Zhou Q, Pories WJ et al. Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes 2000; 49:1353-8.
47. Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001;44:659-73.
48. Houdali B, Nguyen V, Ammon HPT et al. Prolonged glucose infusion into conscious rats inhibits early steps in insulilin signaling and induces translocation of GLUT4 and protein kinase C in skeletal muscle. Diabetologia 2002;45:356-68.
49. He Z, King GL. Protein kinase C beta isoform inhibitors. Circulation 2004;110:7-9.
50. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28:2686-90.
51. Alello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Investig Ophthalmol Vis Sci 2006;47:86-92.
52. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-KB. Nature Med 2005;11:183-90.
53. Arkan MC, Hevener AL, Greten FR et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nature Med 2005;11:191-8.
54. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IkkB. Science 2001;293:1673-7.
55. Kaneto H, Nakatani Y, Miyatsuki T et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nature Med 2004;10:1128-32.
56. Gual P, Gremeaux T, Gonzalez T, Le Marchand-Brustel Y, Tanti JF. MAP kinases and mTOR mediate insulin-induced phosphorylation of Insulin Receptor Substrate-1 on serine residues 307, 612 and 632. Diabetologia 2003;46:1532-42.
57. Dong H, Maddox BA, Altomonte J et al. Increased hepatic levels of the insulin receptor inhibitor, PC-1/NNP1, induce insulin resistance and glucose intolerance. Diabetes 2005;54:367-72.
58. Fleming A, Gunn R, Longo R, Sleevi M, Gregory J, Rogol A. Evaluation of D-chiro-inositol (INS-1) in combination with sulphonylureas on glycaemic control and lipids in subjects with type 2 diabetes mellitus. Diabetes 2001;50(suppl 2):A112, A448.
59. Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Br J Pharmacol 2000;130:1944-8.
60. Kim HJ, Ku B, Lee J, Lee SK, Kim Y, Park K. The effects of pinitol on glycaemic control and adipokine levels in type 2 diabetes patients. Diabetologia 2006;49(suppl 1):A0857.
61. Brautigan DL, Brown M, Grindrod S. Allosteric activation of protein phosphatase 2C by D-chiro-inositol-galactosamine, a putative mediator mimetic of insulin action. Biochemistry 2005;44:11067-73.
62. Butler M, McKay RA, Popoff IJ et al. Specific inhibition of PTEN expression reverses hyperglycaemia in diabetic mice. Diabetes 2002;51:1028-34.
63. Komazawa N, Matsuda M, Kondoh G et al. Enhanced insulin sensitivity, energy expenditure and thermogenesis in adipose-specific PTEN suppression in mice. Nature Med 2004;10:1208-15.
64. Beguinot F. PTEN: targeting the search for novel insulin sensitizers provides new insight into obesity research. Diabetologia 2007;50: 247-9.
65. Clement S, Krause U, Tanti JF et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001;409:92-7.
66. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Nutr Metab Care 2002;5:551-9.
67. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of a human engineered anti-TNF-alpha antibody (SDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5.
68. Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia 2004;47:1135-42.
69. Williams KV, Kelley DE. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diab Obesity Metab 2000;2:121-9.
70. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55:1537-45.
71. Al-Daghri N, Bartlett WA, Jones AF, Kumar S. Role of leptin in glucose metabolism in type 2 diabetes. Diab Obesity Metab 2002;4:147-55.
72. Bates SH, Myers MG. The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab 2003;14: 447-52.
73. Bates SH, Gardiner JV, Jones RB, Bloom SR, Bailey CJ. Acute stimulation of glucose uptake by leptin in L6 muscle cells. Horm Metab Res 2002;34:111-15.
74. Heymsfield SB, Greenberg AS, Kujoka K, Dixon RM. Recombinant leptin for weight loss in obese and lean adults: a randomized controlled dose escalation trial. JAMA 1999;282:1568-75.
75. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-6.
76. Petersen KF, Oral AE, Dufour S et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-50.
77. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
78. Sul HS. Resistin/ADSF/FIZZ3 in obesity and diabetes. Trends Endocrinol Metab 2004;15:247-9.
79. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity and type 2 diabetes. Lancet 2002;359:46-7.
80. Beltowski J. Adiponectin and resistin - new hormones of white adipose tissue. Med Sci Monit 2003;9:RA55-61.
81. Yamauchi T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001;7:941-6.
82. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-51.
83. Stefan N, Vozarova B, Funahasi T et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;50:1884-8.
84. Gable DR, Hurel SI, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, metabolic syndrome and cardiovascular disease. Atherosclerosis 2006;188:231-44.
85. Maeda N, Takahashi M, Funahashi T et al. PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose derived protein. Diabetes 2001;50:2094-9.
86. Fukuhara A, Matsuda M, Niisizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307: 366-7.
87. Berndt J, Kloting N, Kralisch S et al. Plasma visfatin concentrations and fat-depot specific mRNA expression in humans. Diabetes 2005;54: 2911-16.
88. Noy N. Retinoid binding proteins: mediators of retinoid action. Biochem J 2000;348:481-95.
89. Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62.
90. Graham TE, Yang Q, Bluher M et al. Retinol binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med 2006;354:2552-63.
91. Hida K,Wada J, Eguchi J et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-15.
92. Yang RZ, Lee MJ, Hu H et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol 2006;290:E1253-E1261.
93. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
94. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006;368:1660-72.
95. Liu Y, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle uptake in Lep ob/Lep ob mice. Int J Obesity 2005;29: 183-7.
96. Bailey CJ, Turner SL, Bates SH, Jones RB. Sibutramine metabolites increase glucose transport by cultured rat muscle cells. Int J Obesity 2001;25:1-8.
97. Coletta DK, Bates SH, Jones RB, Bailey CJ. The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data. Diabetes Vasc Dis Res 2006;3:186-8.
98. Coleman MD, Eason RC, Bailey CJ. The therapeutic use of lipoic acid in diabetes: a current perspective. Env Tox Pharmacol 2001;10:167-72.
99. Eason RC, Archer HE, Akhtar S, Bailey CJ. Lipoic acid increases glucose uptake by skeletal muscles of obese-diabetic ob/ob mice. Diab Obesity Metab 2002;4:29-35.
100. Yaworsky K, Somwar R, Ramial T, Tritschler HJ, Klip A. Engagement of the insulin-sensitive pathway in the stimulation of glucose transport by alpha-lipoic acid in 3T3-L1 adipocytes. Diabetologia 2000;43: 294-303.
101. Konrad D, Somwar R, Sweeney G et al. The antihyperglycemic drug α-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation. Diabetes 2001;50:1464-71.
102. Schwartz SL. Bromocriptine (Ergoset) improves glycemic control in type 2 diabetics on insulin. Diabetes 1999;48(suppl 1):A99,A427.
103. Liu IM, Hsu FL, Chen CF, Cheng JT. Antihyperglycemic action of isoferulic acid in streptozotocin-induced diabetic rats. Br J Pharmacol 2000;129:631-6.
104. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004;64:2537-65.
105. The DREAM trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62.
106. Arbin V, Claperon N, Fournie-Zaluski MC, Roques BP, Peyroux J. Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br J Pharmacol 2001;133:495-502.
107. Damas J, Hallet C, Lefebvre PJ. Changes in blood glucose and plasma insulin levels induced by bradykinin in anaesthetized rats. Br J Pharmacol 2001;134:1312-18.
108. Das UN. Is angiotensin II an endogenous pro-inflammatory molecule? Med Sci Monit 2005;11:RA155-62.
109. Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989;12:553-64.
110. Day C. Traditional plant treatments for diabetes mellitus. Acta Chim Therap 2000;26:131-50.
111. Simmonds MSJ, Howes MJR. Plants used in the treatment of diabetes. In: Traditional Medicines for Modern Times: Antidiabetic Plants. Soumyanath A (ed), Boca Raton: CRC Press and Taylor and Francis, 2006, pp19-82.
112. Reed MJ, Meszaros K, Entes LJ et al. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of type II diabetes. Diabetologia 1999;42:102-06.
113. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nature Revs 2006;5:493-506.
114. Lagouge M, Argmann C, Gerhart-Hines Z et al. Resveratrol improves mitochondrial function and protects against metabolic diseases bv activating SIRT1 and PGC-1 alpha. Cell 2006;127:1109-22.
115. Bailey CJ. New drugs for the treatment of diabetes mellitus. In: International textbook of diabetes, 3rd Edn, DeFronzo RA, Ferannini E, Keen H, Zimmet P eds. Chichester, England: John Wiley and Sons; 2004, pp951-79.
116. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005;26:244-51.
117. Bailey CJ. Drugs on the horizon for diabesity. Curr Diabetes Reps 2005;5:353-9.
118. Nolte RT, Wisely GB, Westin S. Ligand binding and co-activator assembly of the peroxisome proliferators-activated receptor gamma. Nature 1998;395:137-43.
119. Camp HS, Li O, Wise SC. Differential activation of peroxisome proliferators activated receptor-γ. Diabetes 2000;49:539-47.
120. Allen T, Zhang F, Moodle SA et al. Halofenate is a selective peroxisome proliferator-activated receptor g modulator with antidiabetic activity. Diabetes 2006;55:2523-33.
121. Murphy GJ, Holder JC. PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000;21:469-74.
122. Puigserver P, Spegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1a (PGC-1a): transcriptional coactivator and metabolic regulator. Endocr Rev 2003;24:78-90.
123. Patti ME, Butte AJ, Crunkhorn S. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003;100: 8466-71.
124. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-88.
125. Bailey CJ. New pharmacologic agents for diabetes. Curr Diab Reps 2001;1:119-26.
126. Conlon D. Goodbye glitazars? Br J Diabetes Vasc Dis 2006;6:135-7.
127. Wang YX, Lee CH, Tiep S et al. Peroxisome proliferators-activated receptor d activates fat metabolism to prevent obesity. Cell 2003;113: 159-70.
128. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nature Med 2004;10:1-7.
129. Oliver W, Wilson J, Winegar D et al. A PPARpan agonist delivers glycemic control and improved lipid profiles without weight gain and hemodilution in rodent models of type 2 DM, dyslipidemia and obesity. Diabetes 2003;52(suppl 1):A453,A1961.
130. Mukherjee R, Davies PJ, Crombie D. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386:407-10.
131. Emilsson V, O'Dowd J, Wang S. The effects of retinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 2000;49:1610-15.
132. Liu Y, Sennitt MV, Hislop DC. Retinoid x receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats. Int J Obesity 2000;24:997-1004.
133. Cha BS, Ciaraldi TP, Carter L. Peroxisome proliferators-activated receptor (PPAR) g and retinoid x receptor (RXR) agonists have complimentary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 2001;44:444-52.
134. Bailey CJ. New pharmacological approaches to glycemic control. Diabetes Revs 1999;7:94-113.
135. American Diabetes Association. Magnesium supplementation in the treatment of diabetes. Diabetes Care 1992;15:1065-7.
136. Anderson RA, Cheng N, Bryden NA et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997;46:1786-91.
137. Martin J, Wang ZQ, Zhang XH et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006;29:1826-32.
138. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin dependent and noninsulin dependent diabetes mellitus. In vivo and in vitro studies. J Clin Endocrinol Metab 1995;80:3311-20.
139. Cohn N, Halberstam M, Shlimovich M, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin dependent diabetes mellitus. J Clin Invest 1995;95:2501-09.
140. Tsiani E, Bogdanovic E, Sorisky A, Nagy L, Fantus IG. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. Diabetes 1998;47:1676-86.
141. Marti L, Abella A, Carpene C, Palacin M, Testar X, Zorzano A. Combined treatment with benylamine and low dosages of vanadate enhances glucose tolerance and reduces hyperglycemia in streptozotocin-induced diabetic rats. Diabetes 2001;50:2061-8.
142. Reul BA, Amin SS, Buchet JP, Ongemba LN, Crans DC, Brichard SM. Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Br J Pharmacol 1999;126:467-77.
143. Bailey CJ. New pharmacological approaches to glycemic control. Diabetes Revs 1999;7:94-113.
144. Shisheva A, Gefel D, Shechter Y. Insulin like effects of zinc ion in vitro and in vivo. Diabetes 1992;41:982-6.
145. Becker DJ, Reul B, Ozvelikay AT, Buchet JP, Henquin JC, Brichard SM. Oral selenate improves glucose homeostasis and partly reverses abnormal expression of liver glycolytic and gluconeogenic enzymes in diabetic rats. Diabetologia 1996;39:3-11.
146. Reul BA, Becker DJ, Ongemba LM, Bailey CJ, Henquin JC, Brichard SM. Improvement of glucose homeostasis and hepatic insulin resistance in ob/ob mice given oral molybdate. J Endocrinol 1997;155:55-64.
147. Munoz MC, Barbera A, Dominguez J, Fernandez-Alvarez J, Gomis R, Guinovart JJ. Effects of tungstate, a new potential oral antidiabetic agent, in Zucker diabetic fatty rats. Diabetes 2001;50:131-8.
148. Barbera A, Gomis RR, Prats N et al. Tungstate is an effective antidiabetic agent in streptozotocin-induced diabetic rats: a long-term study. Diabetologia 2001;44:507-13.
149. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440: 944-8.
150. Frank GD, Eguchi S, Motley ED. The role of reactive oxygen species in insulin signaling in the vasculature. Antioxid Redox Signal 2005;7: 1053-61.
151. Opara EC, Abdel-Rahman E, Soliman S et al. Depletion of total antioxidant capacity in type 2 diabetes. Metabolism 1999;48:1414- 17.
152. Coleman MD. Monitoring diabetic antioxidant status: a role for in vitro methaemoglobin formation. Env Tox Pharmacol 2001;10:207-13.
153. Kaneto H, Kajimoto Y, Miyagawa J et al. Beneficial effects of antioxidants in diabetes. Diabetes 1999;48:2398-406.
154. Sargeant LA, Wareham NJ, Bingham S et al. Vitamin C and hyperglycemia in the European Prospective Investigation into cancer. Norfolk (EPIC-Norfolk) study. Diabetes Care 2000;23:726-32.
155. Ford ES. Vitamin supplement use and diabetes mellitus incidence among adults in the United States. Am J Epidemiol 2001;153:892-7.
156. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360: 23-33.
157. Manning PJ, Sutherland WH, Walker RJ et al. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabetes Care 2004;27:2166-71.
158. Fernandez-Mejia C, Zendejas-Ruiz I, Revilla-Monsalve C, Islas-Andrede S. Biotin treatment increases insulin sensitivity in type 2 diabetics (T2D). Diabetes 2003;52(suppl 1):A459,A1987.
159. Bakker SJL, Hoogeveen EK, Nijpels G et al. The association of dietary fibres with glucose tolerance is partly explained by concomitant intake of thiamine: the Hoorn study. Diabetologia 1998;41:1168-75.
160. Reynolds RM, Walker BR. Human insulin resistance: the role of glucocorticoids. Diabetes Obesity Metab 2003;5:5-12.
161. Stewart PM, Krozowski ZS. 11B-hydroxysteroid dehydrogenase. Vitam Horm 1999;57:249-324.
162. Alberts P, Engblom L, Edling N et al. Selective inhibition of 11B-hydroxysteriod dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002;45:1528-32.
163. Alberts R Nilsson C, Selen G et al. Selective inhibition of 11 beta hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003;144:1455-72.
164. Perrini S, Natalicchio A, Laviola L et al. Dehydroepandrosterone stimulates glucose uptake in human and murine adipocytes by inducing GLUT1 and GLUT4 translocation to the plasma membrane. Diabetes 2004;53:41- 52.
165. Hardie DG. The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003;144:5179-83.
166. Pold R, Jensen LS, Jessen LS et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 2005;54:928-34.
167. Iglesias MA, Furler SM, Cooney GJ, Kraegen EW, Ye JM. AMP-activated protein kinase activation by AICAR increases both muscle fatty acid and glucose uptake in white muscle of insulin-resistant rats in vivo. Diabetes 2004;53:1649-54.
168. Motoshima H, Goldstein BJ, Igata M, Araki E. AmPK and cell proliferation: AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006;574:63-71.
169. McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7-18.
170. Krebs M, Roden M. Molecular mechanisms of lipid induced insulin resistance in muscle, liver and vasculature. Diabetes Obesity Metab 2005;7:621-32.